Bionomics intends to re-domicile to the U.S.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 01 2024
0mins
Should l Buy ?
Bionomics Re-domiciliation Announcement: Bionomics plans to re-domicile from Australia to the U.S. through a scheme that requires shareholder and regulatory approval, aiming to reduce compliance costs and streamline operations.
Shareholder Impact and Voting: Upon approval, Bionomics shareholders will receive shares in the new parent company, Neuphoria Therapeutics, with a vote scheduled for late November; the board recommends supporting the Scheme.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
